[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630608":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":69,"collaborators":30,"id":71,"slug":30,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":30,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":44,"whyStopped":30,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"InventisBio Co., Ltd","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"D-2570 low dose","ACTIVE_COMPARATOR","Low dose of D-2570",[13],"Drug: D-2570 Tablet",{"label":15,"type":10,"description":16,"interventionNames":17},"D-2570 High Dose","medium dose level of D-2570",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo","PLACEBO_COMPARATOR","Placebo arm",[23],"Drug: Placebo Tablets",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","D-2570 Tablet","Active Treatment",[15,9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Placebo Tablets","Identical Tablet",[19],[36],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"Kathryn Stazzone","CONTACT","3025195966","kathryn.stazzone@inventisbio.com",[42,58],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Study Center","RECRUITING","Birmingham","Alabama","35244","United States",{"type":50,"coordinates":51},"Point",[52,53],-86.80249,33.52066,{"lat":53,"lon":52},[56],{"name":37,"role":38,"phone":57,"phoneExt":30,"email":40},"302-519-5966",{"facility":43,"status":44,"city":59,"state":60,"zip":61,"country":48,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Chula Vista","California","91910",{"type":50,"coordinates":63},[64,65],-117.0842,32.64005,{"lat":65,"lon":64},[68],{"name":37,"role":38,"phone":57,"phoneExt":30,"email":40},{"type":70,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100630608",false,"NCT07489885","A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis","N\u002FZ","Inclusion Criteria:\n\n* Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent\n* Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.\n* Within normal ranges of laboratory assessments\n\nExclusion Criteria:\n\n* Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator","ALL","18 Years","70 Years",{"count":82,"type":83},75,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis",[89],"Psoriasis",[91],"Moderate to Severe Plaque Psoriasis","2026-06-17",{"date":94,"type":95},"2026-06-22","ACTUAL",{"date":97,"type":95},"2026-06-03",{"date":99,"type":83},"2027-12",{"name":5,"class":6},2]